Abstract #0703

Prospective Validation of an Automated Hybrid Multidimensional MRI Based Tool to Identify Areas for Prostate Cancer Biopsy: Preliminary results

Aritrick Chatterjee¹, Carla Harmath¹, Roger Engelmann¹, Ajit Devaraj², Ambereen Yousuf¹, Scott Eggener³, Glenn Gerber³, Gregory Karczmar¹, and Aytekin Oto¹

¹Department of Radiology, University of Chicago, Chicago, IL, United States, ²Philips Research North America, Chicago, IL, United States, ³Department of Urology, University of Chicago, Chicago, IL, United States

This prospective clinical trial evaluates whether HM-MRI identifies PCa more reliably than random biopsy and/or targets detected based on PI-RADSv2. Patients underwent 3T mpMRI along with HM-MRI. Patients received 12-core TRUS-guided sextant random biopsy. Additional biopsy targets selected by radiologist (≥PI-RADS 3) and suspected PCa based on HM-MRI tissue composition estimates were biopsied, using a Uronav MR-US fusion biopsy device. The diagnostic accuracy of HM-MRI for detecting clinically significant cancers was higher than that of mpMRI on per-tumor (0.74 vs 0.61) and sextant analysis (0.84 vs 0.75). HM-MRI had higher accuracy, sensitivity, specificity and PPV than mpMRI, with similar NPV.

This abstract and the presentation materials are available to members only; a login is required.

Join Here